The recent discovery of small molecules targeting the cytochrome bc 1 :aa 3 in Mycobacterium tuberculosis triggered interest in the terminal respiratory oxidases for antituberculosis drug development. The mycobacterial cytochrome bc 1 :aa 3 consists of a menaquinone:cytochrome c reductase (bc 1 ) and a cytochrome aa 3 -type oxidase. The clinical-stage drug candidate Q203 interferes with the function of the subunit b of the menaquinone:cytochrome c reductase. Despite the affinity of Q203 for the bc 1 :aa 3 complex, the drug is only bacteriostatic and does not kill drug-tolerant persisters. This raises the possibility that the alternate terminal bd-type oxidase (cytochrome bd oxidase) is capable of maintaining a membrane potential and menaquinol oxidation in the presence of Q203. Here, we show that the electron flow through the cytochrome bd oxidase is sufficient to maintain respiration and ATP synthesis at a level high enough to protect M. tuberculosis from Q203-induced bacterial death. Upon genetic deletion of the cytochrome bd oxidase-encoding genes cydAB, Q203 inhibited mycobacterial respiration completely, became bactericidal, killed drugtolerant mycobacterial persisters, and rapidly cleared M. tuberculosis infection in vivo. These results indicate a synthetic lethal interaction between the two terminal respiratory oxidases that can be exploited for anti-TB drug development. Our findings should be considered in the clinical development of drugs targeting the cytochrome bc 1 :aa 3 , as well as for the development of a drug combination targeting oxidative phosphorylation in M. tuberculosis.
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bioenergetics | oxidative phosphorylation | persisters | Q203 | bedaquiline T he emergence and spread of drug resistance in pathogenic mycobacteria poses serious global health concerns. Tuberculosis (TB) continues to cause 1.4 million deaths in HIVnegative individuals and 10.4 million new cases in 2015 (1) . It was recently evaluated that the number of TB cases in India is two to three times higher than previously estimated (2) , suggesting that the global number of TB cases may be largely underestimated. Despite progress in public health management and the use of fixed-dose combinations, the number of multi-and extensively drug-resistant (M-XDR) TB cases continues to rise (1) . According to the last WHO report, the proportion of multidrugresistant tuberculosis among newly diagnosed cases is a staggering 5.6% (1) . In 2015, 580,000 new patients were eligible for MDR-TB treatment. MDR-TB treatment is challenging because it requires the administration of second-line drugs for up to 2 y (3), with an estimated global success rate of 52% and an unacceptable mortality rate (3) . There is a pressing clinical need for the development of new drugs able to shorten the treatment of MDR-TB to 6 mo or less. More than new drugs, a rational drug combination made of complementary agents is urgently needed.
Despite increasing interest from the scientific community, the global drug pipeline remains thin: only a very few new chemical entities have entered clinical development in the last 40 y (4) . The recent approval of bedaquiline (BDQ, Sirturo) represents a critical milestone in anti-TB drug discovery (5) (6) (7) . Nevertheless, the successful advance of BDQ is overshadowed by the emergence of clinical resistance less than 3 y after its introduction to medical use (8) . The rapid emergence of resistance is most likely linked to the absence of potent companion drugs. Indeed, BDQ is currently given in combination with weaker second-and third-line drugs, imposing a strong selection pressure for BDQ resistance. This reinforces the notion that a rational drug combination of complementary drugs is required to shorten the treatment time of MDR-TB.
The discovery of BDQ, a potent inhibitor of the mycobacterial F 1 F o -ATP synthase, validated oxidative phosphorylation (OxPhos) (Fig. 1) as an attractive drug target in M. tuberculosis. OxPhos is an ubiquitous metabolic pathway, in which the energy contained in nutrients is used to generate an electrochemical gradient, also called the proton motive force (pmf), that drives the synthesis of Significance New drugs are needed to combat multidrug-resistant tuberculosis. The electron transport chain (ETC) maintains the electrochemical potential across the cytoplasmic membrane and allows production of ATP, the energy currency of any living cell. The ETC of the tubercle bacilli contains two terminal oxidases, the cytochrome bc 1 :aa 3 and the cytochrome bd oxidase. In this study, we used genetics and chemical biology approaches to demonstrate that simultaneous inhibition of both terminal oxidases stops respiration, kills nonreplicating drugtolerant Mycobacterium tuberculosis, and eradicates infection in vivo at an extraordinarily fast rate. Exploiting this potent synthetic lethal interaction with new drugs promises to shorten tuberculosis chemotherapy.
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This article is a PNAS Direct Submission. Adenosine Tri-Phosphate (ATP). The pmf is required for the survival of both replicating and nonreplicating (often referred to as dormant) mycobacteria (9, 10) . Dissipation of the pmf leads to a rapid loss of cell viability and cell death. Therefore, drugs targeting enzymes involved in pmf generation are predicted to reduce time of therapy by killing phenotypic drug-resistant bacterial subpopulations (11) .
In M. tuberculosis, the generation of the pmf is mediated primarily by the proton-pumping components of the electron transport chain (ETC). Under aerobic conditions, the ETC of M. tuberculosis branches into two terminal oxidases; the protonpumping cytochrome bc 1 -aa 3 supercomplex (Cyt-bc 1 :aa 3 ) and the less energy efficient, but higher-affinity cytochrome bd oxidase (Cyt-bd) (12) (13) (14) (15) . In recent years, the discovery of several small molecules targeting the Cyt-bc 1 :aa 3 branch (16-21) has triggered interest in the heme-copper respiratory oxidase (18, 20) . All small-molecule inhibitors discovered to date seem to target the cytochrome b subunit of the bc 1 complex (16-21). The best characterized compounds targeting cytochrome bc 1 are a series of imidazopyridine amides (IPA) (16, (18) (19) (20) . The most advanced IPA derivative is Q203, a drug candidate currently in clinical trial phase I under a US FDA Investigational New Drug application (22) . However, despite the reported susceptibility of the Cyt-bc 1 :aa 3 to chemical inhibition, the influence of the alternative Cyt-bd terminal oxidase on the potency of Q203 and related drugs remains to be defined. Here, through a combination of chemical biology and genetic approaches, we reveal the existence of a synthetic lethal interaction between the Cyt-bc 1 :aa 3 and the Cyt-bd terminal oxidases. A synthetic lethal interaction is a well-described phenomenon where the single inactivation of two genes has little effect on cell viability, whereas the simultaneous inactivation of both genes results in cell death (23) . Upon chemical inhibition of the Cyt-bc 1 :aa 3 complex, respiration through Cyt-bd is sufficient to maintain the viability of replicating and nonreplicating mycobacteria. However, simultaneous inhibition of both terminal oxidases was sufficient to inhibit respiration, kill phenotypic drug-resistant persisters, and rapidly eradicate M. tuberculosis infection in vivo.
Results

Q203 Is a Bacteriostatic Agent that Does Not Inhibit Oxygen Respiration.
The metabolic consequences of the chemical inhibition of the mycobacterial Cyt-bc 1 :aa 3 have not been studied in detail. A recent study revealed that Q203 and BDQ treatment triggered an increase in oxygen consumption rate (OCR) up to 16 h posttreatment, which is counterintuitive given the capacity of the drugs to interfere with respiration. Interestingly, increase in OCR was only observed at a very high dose of drugs (300× MIC), but not at an intermediate dose (30× MIC) (24) . Consequently, we were interested in gaining more mechanistic insight into the ETC adaptations to Q203 and BDQ and their long-term effects on oxygen respiration. Using methylene blue as an oxygen probe, we made the observation that oxygen consumption was significantly inhibited by BDQ treatment over a 96-h period, but was unaffected by Q203 treatment (Fig. 2A) . To ensure that these results were not an artifact due to the inability of inhibitors of the Cyt-bc 1 :aa 3 to inhibit growth of laboratory strains of M. tuberculosis (17), we verified the potency of Q203 against five clinical isolates (N0052, N0072, N0145, N0157, N0155) from different M. tuberculosis lineages (25) and M. bovis bacillus Calmette-Guérin. We confirmed that Q203 has excellent growth inhibitory potency against all these strains (Fig. 2B ). Q203 had a Minimum Inhibitory Concentration leading to 50% growth inhibition (MIC 50 ) of 1.5-2.8 nM, whereas BDQ was active in a MIC 50 range of 42-133 nM (Fig. 2B and Table S1 ). Altogether, these results suggested that chemical inhibition of the Cyt-bc 1 :aa 3 terminal oxidase led to bacterial growth arrest without affecting oxygen consumption. Because BDQ inhibited oxygen respiration over a 96-h period, whereas Q203 did not ( Fig. 2A) , we were next interested in testing the correlation between inhibition of oxygen consumption and bacterial death. Interestingly, we observed that despite the superior potency of Q203 in the growth inhibition assay, the drug candidate was much less effective at killing M. tuberculosis compared with BDQ. BDQ was bactericidal against four strains of M. tuberculosis at a concentration 5-to 12-fold above its MIC 50 (Fig. 2C) , whereas Q203 was bacteriostatic even at doses exceeding 200-fold its MIC 50 (Fig. 2C) . Similar results were observed in Mycobacterium bovis bacillus Calmette-Guérin (Fig. S1 ). Because BDQ and Q203 target the same pathway (OxPhos), but have a striking difference on mycobacterial viability, we hypothesized that an alternate branch of the ETC may compensate for the chemical inhibition of the Cyt-bc 1 :aa 3 terminal oxidase.
Cytochrome bd-Type Oxidase Compensates for Chemical Inhibition of the Cytochrome bc 1 :aa 3 Branch. The involvement of Cyt-bd in a possible compensatory mechanism was investigated. The cydAB genes (coding for Cyt-bd) were deleted in M. tuberculosis H37Rv and Mycobacterium bovis bacillus Calmette-Guérin (bacillus Calmette-Guérin), leading to strains H37Rv ΔcydAB, and bacillus Calmette-Guérin ΔcydAB. Deletion of cydAB did not impact significantly on bacterial growth and ATP homeostasis (Fig.  S2 ). The synthetic lethal interaction between the Cyt-bc 1 :aa 3 and the Cyt-bd was evaluated by treating the mutant strains with Q203. Deletion of cydAB had a modest effect on the growth inhibitory potency of Q203 (Fig. S3) , but a profound impact on the capacity of mycobacteria to respire with oxygen over a prolonged period (Fig. 3 ). Using methylene blue as an oxygen probe, we observed that treatment of H37Rv ΔcydAB or bacillus Calmette-Guérin ΔcydAB with Q203 led to an apparent complete inhibition of oxygen respiration (Fig. 3 , Insets, and Fig. S4 ). This phenotype was reversed by expressing the cydAB operon in the mutant strains (ΔcydABcomp strains) (Fig. 3 , Insets, and Fig.  S4 ). The inability of the Cyt-bd mutant to utilize oxygen was confirmed by measuring the Relative Oxygen Consumption rate (ROC) using the MitoXpress Oxygen probe in whole cells over a short period (Fig. 3 ). Under our experimental conditions, Q203 had no significant effect on oxygen respiration in the parental strain, but triggered a complete inhibition of oxygen consumption in H37Rv ΔcydAB at an IC 50 of 3.1 nM (Fig. 3 B and D). These results were corroborated in inverted membrane vesicles with NADH as the electron donor (Fig. S5 ). Furthermore, Q203 treatment led to a decrease in ATP levels in the parental H37Rv strain, but to a lesser extent compared with BDQ treatment (Fig. 4A ). Q203 treatment was more effective at disrupting ATP homeostasis in H37Rv ΔcydAB compared with the parental strain (Fig. 4B) . Similar results were obtained in bacillus Calmette-Guérin (Fig. S6 ). Because the effect on oxygen consumption correlated with reduced ATP levels in Q203-treated ΔcydAB strains, we hypothesized that electron flow diverted to the Cyt-bd branch upon chemical inhibition of the Cyt-bc 1 :aa 3 was sufficient to maintain cell viability. Consistent with this hypothesis, Q203 displayed a dose-dependent bactericidal effect against H37Rv ΔcydAB (Fig. 4D ). Under the same conditions, the bactericidal potency of BDQ was unaffected by cydAB deletion (Fig. 4D) . Similar results were obtained in bacillus Calmette-Guérin (Fig. S6D) . Altogether, these findings established a strong synthetic lethal interaction between Cyt-bc 1 :aa 3 and Cyt-bd and the requirement for at least one terminal oxidase to maintain cell viability in mycobacteria.
Cytochrome bd-Type Oxidase Protects Nonreplicating Mycobacteria from Q203-Induced Bacterial Death. Next, the impact of Q203 treatment on ATP homeostasis and viability of nutrient-starved, phenotypic drug-resistant mycobacteria was evaluated. Q203 treatment in the parental strain resulted in a dose-dependent reduction in ATP levels, but without affecting cell viability (Fig. 5 A and C) . Under similar experimental conditions, BDQ was bactericidal (Fig. 5C ). It was noted that ATP depletion induced by Q203 treatment in the parental strain was significantly less compared with BDQ treatment (Fig. 5 A and B) . As observed under replicating conditions, Q203 treatment triggered a more profound ATP depletion in the nutrient-starved H37Rv ΔcydAB strain compared with the parental strain (Fig. 5A ) and was bactericidal (Fig. 5C) . The effect on cell viability was profound because Q203 at 100 nM killed more than 99.99% of the nonreplicating H37Rv ΔcydAB strain (Fig. 5C ). The phenotype was reversed in the H37Rv ΔcydABcomp strain (Fig. 5C) . Similar results were obtained in bacillus Calmette-Guérin (Fig. S7) . These data further demonstrated that the respiratory terminal oxidases are jointly required for oxidative phosphorylation and that simultaneous inactivation of both has a striking effect on the viability of nonreplicating, phenotypically drug-resistant mycobacteria.
Synthetic Lethal Interaction Between the Respiratory Terminal
Oxidases During Infection. To test whether the synthetic lethal interaction between the Cyt-bc 1 :aa 3 and the Cyt-bd was relevant during infection, the potency of Q203 was evaluated against the H37Rv, H37Rv ΔcydAB, and complemented strains replicating in THP-1 cells. Bacterial viability was evaluated after 5 d of treatment with Q203 or BDQ. Results revealed that the multiplication profile of the H37Rv ΔcydAB strain was comparable to the parental H37Rv strain (Fig. 6 A and B) , suggesting that the Cyt-bd alone does not contribute to growth in macrophages. As reported before, Q203 was active against the parental H37Rv strain replicating in macrophages (18, 20) . However, the effect of the drug candidate was bacteriostatic (Fig. 6A) . In line with the in vitro phenotypes, Q203 was bactericidal against the H37Rv ΔcydAB strain replicating in THP-1 cells (Fig. 6B) . BDQ was active against intracellular mycobacteria, regardless of the presence of the Cyt-bd (Fig. 6 A-C) . Phenotypes were reverted in the H37Rv ΔcydABcomp strain (Fig. 6C) . This result showed that oxygen respiration contributes to the virulence of M. tuberculosis in a macrophage model and that at least one of the terminal oxidases was required for respiration and energy production in an ex vivo infection model. This finding prompted us to investigate the joint essentiality of the terminal oxidases in a mouse model of tuberculosis. BALB/c mice infected by the aerosol route with the H37Rv, ΔcydAB, and ΔcydABcomp strains were treated with Q203 at 2 mg/kg, BDQ at 10 mg/kg, or with the vehicle control three times per week. The H37Rv ΔcydAB strain had no obvious attenuation phenotype during the course of the infection, but was dramatically more sensitive to Q203 compared with the parental H37Rv or ΔcydABcomp strains (Fig. 6 D-F) . During the first 2 wk of treatment, Q203 reduced the bacterial load in the lungs of animals infected by the mutant strain by more than 99% (Fig. 6D) . During the same time frame, Q203 had no significant efficacy against the parental strain (Fig. 6D) . Strikingly, after 4 wk of treatment, the bacterial count in the mice infected by the H37Rv ΔcydAB strain and treated with Q203 had dropped below the limit of detection in 3 out of 5 mice (Fig. 6D) . Using this suboptimal dosing regimen, Q203 had no significant effect against the parental H37Rv and the ΔcydABcomp strains (Fig. 6D) . Although BDQ was effective against the parental strain, there was still an eightfold increase in sensitivity of the H37Rv ΔcydAB strain compared with the parental strain after 4 wk of BDQ treatment (Fig. 6F) . It was interesting to note that the potency of Q203 against the H37Rv ΔcydAB strain was radically superior compared with BDQ ( Fig. 6 D and F) . Gross lung pathology (Fig. 6 G-I ) and H&E staining (Fig. S8) corroborated these results. Lungs infected with H37Rv ΔcydAB and treated with Q203 showed no signs of typical lesions, nor any inflammation foci after 4 wk of treatment (Fig. 6G and Fig. S8A ). In contrast, multiple lesions and inflamed foci were found in the lungs of the mice infected with the parental, or the complemented strain, that were treated by Q203 (Fig. 6G and Fig. S8 D and G) . These results demonstrate the efficacy of a therapeutic approach that exploits the synthetic lethal interaction between Cyt-bc 1 :aa 3 and Cyt-bd oxidases. Discussion M. tuberculosis is an obligate aerobe that can survive, but not replicate, under hypoxic conditions. The reasons for the strict dependence on oxygen for growth are poorly understood but illustrate the prominence of aerobic respiration and the terminal respiratory oxidases for the biology of this bacterium (11) . In the past 10 y the discovery of drugs active against enzymes of the mycobacterial oxidative phosphorylation pathway, namely, inhibitors of ATP-synthase (BDQ) and Cyt-bc 1 :aa 3 (imidazopyridine amides), have confirmed this vulnerability. Here, we show that rapid killing and bactericidal activity against M. tuberculosis can be achieved by exploiting the synthetic lethal interaction between the two terminal oxidases of the electron transport chain.
Synthetic lethal relationships likely arise in biological systems to create functional redundancies that mitigate the impact of loss-of-function mutations or inhibition of a single enzyme. The presence of two terminal respiratory oxidases is a perfect example of such a functional redundancy. In this study, we confirmed that chemical inhibition of the Cyt-bc 1 :aa 3 branch by Q203 inhibited mycobacterial growth at a very low dose, but revealed that the drug candidate was not bactericidal even at a concentration 200-fold in excess of its MIC 50 . We demonstrated that respiration through the alternate Cyt-bd terminal oxidase alone is sufficient to maintain mycobacterial viability but insufficient to sustain growth. This discrepancy is likely due to a difference in energetic efficiency of the two terminal oxidases as the Cyt-bc 1 :aa 3 complex pumps 6 protons per 2 electrons (H + /e − ratio of 3), whereas the ratio is only 1 H + /e − for Cyt-bd (11, 26, 27) , and this might also explain the failure to isolate deletion mutants of genes that encode Cyt-bc 1 :aa 3 in M. tuberculosis (28, 29) . As a logical consequence of the functional redundancy, deletion of cydAB led to hypersusceptibility to Q203 with complete inhibition of oxygen consumption, an enhanced effect on ATP homeostasis, and bactericidal action at low dose against replicating and nonreplicating mycobacteria. Importantly, our results show that oxygen respiration is essential for the survival of nutrient-starved, phenotypic drug-resistant mycobacteria, validating avenues for drug development. Under the in vitro conditions used in this study, the presence of the Cyt-bd did not influence the potency of BDQ. A recent report demonstrated that the early killing rate of BDQ is enhanced in an M. tuberculosis ΔcydA strain (12). Our results are not necessarily in contradiction because in the present study, the bactericidal potency of BDQ was determined at only one late time point. The observation that the H37Rv ΔcydAB strain has a slight, yet significant increase in sensitivity to BDQ compared with the parental strain in the mouse model supports the previous observation (12) . The most critical finding of this study is the rapid clearance of the H37Rv ΔcydAB strain by Q203 in a mouse model of tuberculosis. After 4 wk of treatment with Q203 at only 2 mg/kg, near-eradication of H37Rv ΔcydAB was achieved, whereas the same drug treatment had no significant effect against the parental strain. This result illustrates the powerful synthetic lethal interaction between both terminal oxidases and demonstrates that, at least in the microenvironment of the mouse lung, M. tuberculosis relies primarily on oxygen respiration to multiply and persist.
The synthetic lethal interaction between the Cyt-bc 1 :aa 3 and the Cyt-bd could have consequences for the clinical development of Q203. Because the electron flow through the Cyt-bd is sufficient to maintain respiration and viability of Q203-treated mycobacteria, it is uncertain if drug candidates targeting the Cyt-bc 1 :aa 3 will show efficacy in humans. An important characteristic of human tuberculosis disease is the manifestation of a range of lesions with different microenvironmental conditions, including varying oxygen tensions (30) . The expression ratio of Cyt-bc 1 :aa 3 and Cyt-bd is likely to play an integral role in the adaptation to this heterogeneity, further underlining the importance of a combination therapy targeting both terminal oxidases. It is possible that Q203, or other advanced derivatives, will be active against human tuberculosis when used in a combination drug therapy. However, based on the data presented here, it is unlikely that inhibition of the Cyt-bc 1 :aa 3 alone would lead to bacterial sterilization under all physiological conditions. To unleash the full potential of drugs targeting the Cyt-bc 1 :aa 3 branch, we advocate for the development of Cyt-bd inhibitors. It was previously suggested that interference with oxidative phosphorylation at multiple levels is a promising anti-TB strategy (24) . Our data indicate that a drug combination targeting simultaneously the Cyt-bc 1 :aa 3 , the Cyt-bd, and the F 1 F o -ATP synthase may represent the cornerstone of a complementary sterilizing drug combination for the treatment of MDR and XDR tuberculosis.
Materials and Methods
Strains and Growth Conditions. M. tuberculosis H37Rv, derivative strains, and clinical isolates (25) were maintained in Middlebrook 7H9 broth medium supplemented with 0.2% glycerol, 0.05% Tween 80, and 10% ADS supplement. Hygromycin (75 μg/mL) or kanamycin (20 μg/mL) were used when required. Glycerol was omitted to determine drug potency. THP-1 cells were maintained in RPMI medium 1640 supplemented with 10% FBS, 2 mM L-glutamine, 10 mM sodium pyruvate, and kanamycin (50 μg/mL).
MIC 50 and MBC 90 Determination. In this study, MIC 50 was defined as the lowest concentration of compound that inhibited bacterial growth by 50%. MIC 50 was determined by the broth microdilution method using a 96-well flatbottom plate as described before (31) . For MBC 90 determination, mycobacterial inoculum adjusted at an OD 600 of 0.005 was incubated in the presence of drugs for 10 d (replicating bacteria) or 15 d (nonreplicating mycobacteria) at 37°C. Bacterial viability was determined by Colony Forming Units (CFUs) determination on agar plate. The Minimum Bactericidal Concentration leading to 90% reduction in CFU was defined as the MBC 90 . Fig. 6 . The Cyt-bc 1 :aa 3 and Cyt-bd are jointly required for growth in macrophages and for virulence in a mouse model. THP-1 cells were infected with the strains H37Rv (A), H37Rv ΔcydAB (B), and H37Rv ΔcydABcomp (C) and treated with 1% DMSO (vehicle control), Q203, or BDQ. Viability of intracellular mycobacteria was determined after 5 d of treatment. Dotted line, initial bacterial load at 1 h postinfection. *Greater than or equal to 90% reduction in bacterial load compared with the initial bacterial load. The means and SDs of three replicates for each experiment are shown. The experiment was repeated once. BALB/c mice were aerosol-infected with either M. tuberculosis H37Rv (red circles), ΔcydAB (green squares), or ΔcydABcomp (blue triangles). Two weeks after infection, treatment was started by oral administration of Q203 at 2 mg/kg, BDQ at 10 mg/kg, or vehicle control three times a week. Bacillary burden (CFU) in lungs of treated animals was assessed after 2 and 4 wk treatment with either (D) Q203, (E) vehicle, or (F) BDQ. To compare drug efficacy between different strains, CFU counts were normalized to the time of treatment start (day 13 after infection). CFU counts are shown in Table S2 . Gross pathology (G, H, I), and H&E staining (Fig. S8 ) was performed on all lung samples to determine severity of disease and level of inflammation. Error bars represent SDs of at least four replicates. An unpaired Student t test was performed between parental and ΔcydAB CFU counts. *P < 0.05; **P < 0.01. Intracellular ATP quantification. The intracellular ATP level was determined with the BacTiter-Glo Microbial Cell Viability Assay (Promega) (10).
Nutrient-Starved Culture. Exponentially growing cultures of M. tuberculosis were harvested by centrifugation and washed twice with prewarmed DPBS (Thermo Fisher Scientific) supplemented with Ca 2+ , Mg 2+ , and 0.025% Tween 80. Cell density was adjusted to OD 600 of 0.15 and incubated for 2 wk at 37°C before testing sensitivity to drugs.
Gene Knockout and Complementation. Two sets of cydAB (Rv1623c-1622c) deletion strains were constructed independently in the K.P. laboratory and in the M.B. laboratory using similar strategies based on the use of the plasmid pYUB1471 (32) . In the K.P. laboratory, the pYUB1471 containing the 5′ and 3′ flank of the cydAB locus was UV-irradiated (33) before electroporation into M. tuberculosis, whereas in the M.B. laboratory, specialized transduction was used as described previously (32) . Complementation plasmids were created by either incorporating the cydABDC operon and its native promoter (330 bp upstream of the coding region) into the pMV306 vector (34) via Gibson cloning (35) (New England Biolabs), resulting in plasmid pMV306-cydABDC, or by cloning the cydAB genes in the pMV306 plasmid under the control of the hsp60 promoter, resulting in the plasmid pMV306-cydAB.
THP-1 Infection Model. THP-1 cells were treated with 200 nM phorbol myristate acetate and were distributed at a density of 3 × 10 6 cells per well in 24-well plates. After 24 h of differentiation, the cell monolayers were infected with M. tuberculosis at a multiplicity of infection of 10 for 60 min. Prewarmed complete RPMI medium with or without the test drugs was added. Q203 was used at 250 nm, whereas BDQ was used at 1,000 nM. Mycobacterial viability was determined after 5 d of infection by CFU determination on agar plates.
Mouse Experiments and Pathology. Mouse studies were performed in accordance with the National Institutes of Health guidelines following the recommendations in the Guide for the Care and Use of Laboratory Animals (36) . The protocols used in this study were approved by the Institutional Animal Care and Use Committee of Albert Einstein College of Medicine (Protocol #20150208). Female BALB/c mice (The Jackson Laboratory) were infected via aerosol infection at a dose intended to yield an infection of 10 3 CFU per mouse. Drug dosing was initiated 13 d postinfection. Drugs were formulated in 20% D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) per 1% DMSO and administered via gavage three times per week. Infection in the lung was determined by CFU determination on agar plates at 13, 27, and 38 d. For pathological analysis and histological staining, lung samples were fixed in 10% (vol/vol) neutral formalin, paraffin embedment, and the tissues were sectioned at 5 μm. Sections were either stained with Hematoxylin & Eosin, or using the Kinyoun method for acid-fast bacilli.
Oxygen Consumption Assays. Oxygen consumption in whole bacteria was measured using methylene blue or the MitoXpress Xtra-Oxygen Consumption Assay (Luxcel Biosciences).
Methylene blue-based assay. Mycobacteria culture adjusted to an OD 600 of 0.3 were preincubated for 4 h in 2-mL screw-cap tubes in the presence of Q203 at 400 nM, BDQ at 500 nM, or 1% DMSO (vehicle control). Methylene blue at 0.001% was added to each tube. The tubes were then tightly sealed, an incubated in an anaerobic jar to avoid oxygen leak.
MitoXpress-based assay. The assay was performed in black 96-well plates (flat, clear bottom). One hundred fifty microliters of mycobacteria culture adjusted to an OD 600 of 0.3 were preincubated for 6 h in the presence of Q203, BDQ, or 1% DMSO. Ten microliters of the MitoXpress oxygen probe was added to each well that was covered with a layer of high-sensitivity mineral oil to restrict oxygen back diffusion. Fluorescence (Ex: 380 nm, Em: 650 nm) was recorded on a BioTeK CYTATION 3 multimode reader.
Supporting Information
Kalia et al. 10 .1073/pnas.1706139114
SI Methods
Preparation of Inverted Membrane Vesicles. Bacillus CalmetteGuérin was grown at 37°C in 7H9-ADS medium. Bacteria were harvested by centrifugation when the cultures reached an OD 600 of 0.8. Five grams of cells (wet weight) were suspended in 20 mL of 50 mM Mops-NaOH (pH 7.5), 2 mM MgCl 2 supplemented with protease inhibitors (protease inhibitor mixture tablets, Roche). Lysozyme (1.2 mg/mL), 1,500 units of DNase I (Sigma), and 6.7 mM MgCl 2 were added, and the cells were incubated under stirring conditions for 45 min at room temperature. The bacteria were then lysed by five passages using a precooled French pressure cell at 25,000 psi (M-110L, Microfluidiser). The lysate was centrifuged at 4,200 g at 4°C for 20 min to remove unbroken bacteria. The supernatant was ultracentrifuged at 450,000 g for 1 h at 4°C. The pellet of Inverted Membrane Vesicles (IMVs) was resuspended in an appropriate volume of 50 mM Mops-NaOH (pH 7.5), 2 mM MgCl 2 , and 15% glycerol. Protein estimation was performed using the BCA Protein assay (Thermo Fisher Scientific).
Oxygen Consumption Assay. The MitoXpress oxygen probe was used to quantify oxygen consumption in IMVs. The IMVs (150 μL of 300 μg/mL) were preincubated for 5 min with a dose range of Q203 or bedaquiline in a prewarmed 50 mM Mes buffer (pH 6.5) supplemented with 2 mM MgCl 2 . NADH was added at a final concentration of 1 mM as electron donor. Ten microliters of the MitoXpress oxygen probe were added to each well and covered with a layer of high-sensitivity mineral oil. Fluorescence (Excitation: 380 nm, Emission: 650 nm) was recorded after 30 min of incubation using a BioTeK CYTATION 3 multimode reader. S4 . The alternate Cyt-bd terminal oxidase contributes to cellular respiration in bacillus Calmette-Guérin. Bacillus Calmette-Guérin (P), bacillus CalmetteGuérin ΔcydAB (M), and bacillus Calmette-Guérin ΔcydABcomp (C) were incubated with the oxygen probe Methylene blue in the presence of 1% DMSO, 400 nM Q203, or 500 nM BDQ in sealed tubes and incubated under an anaerobic atmosphere to prevent oxygen leak. Pictures were taken after 4 d of incubation at 37°C. The ratio between the MIC 50 and the MBC 90 is shown. Experiments were performed in triplicate and repeated at least once. MIC 50 results are expressed as the mean ± SDs of a representative experiment. n.d., not determined. BALB/c mice were aerosol-infected with either the M. tuberculosis H37Rv, ΔcydAB, or ΔcydABcomp strains. Treatment with Q203, BDQ, or with the vehicle control was initiated 14 d postinfection. Bacillary burden (CFU) in lungs of infected animals was assessed after 2 wk (day 27) and 4 wk (day 38) of drug treatment. Bacterial burden was also assessed at day 1 and day 13 postinfection to confirm bacterial colonization before drug treatment. The average of four mice per time point and per condition is shown.
